A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of laropiprant (LRPT) to reduce flushing symptoms
beyond 6 months and will measure the impact of withdrawal of laropiprant in patients
following 20 weeks of stable maintenance therapy.